A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
- Geneesmiddel: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
- Geneesmiddel: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Ruihua Xu, Doctor
- Telefoonnummer: 020-87343468
- E-mail: xurh@syscc.org.cn
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Nog niet aan het werven
- Peking University First Hospital
-
Contact:
- Shikai Wu, Doctor
- Telefoonnummer: 15810037307
- E-mail: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Nog niet aan het werven
- The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Tao Zhang, Doctor
- Telefoonnummer: 13708311156
- E-mail: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730050
- Nog niet aan het werven
- Gansu Provincial Tumor Hospital
-
Contact:
- Zhihu Li, Master
- Telefoonnummer: 18993042850
- E-mail: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, China, 528000
- Nog niet aan het werven
- The First People's Hospital of Foshan
-
Contact:
- Wei Wang, Doctor
- Telefoonnummer: 18038863618
- E-mail: wangwei@fsyyy.com
-
Guangzhou, Guangdong, China, 510060
- Werving
- Sun Yat-sen University Cancer Center
-
Contact:
- Ruihua Xu, Doctor
- Telefoonnummer: 020-87343468
- E-mail: xurh@syscc.org.cn
-
Guangzhou, Guangdong, China, 510000
- Nog niet aan het werven
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Yanhon Den, Doctor
- Telefoonnummer: 13925106525
- E-mail: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, China, 530000
- Nog niet aan het werven
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Contact:
- Rong Liang, Doctor
- Telefoonnummer: 18677070811
- E-mail: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, China, 563000
- Werving
- The Affiliated Hospital of Zunyi Medical University
-
Contact:
- Jiwei Wang, Doctor
- Telefoonnummer: 18013964231
- E-mail: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Nog niet aan het werven
- Harbin Medical University Cancer Hospital
-
Contact:
- Tongsen Zheng, Doctor
- Telefoonnummer: 15134569619
- E-mail: zhengtongsen@126.com
-
Contact:
- Yuxian Bai, Doctor
- Telefoonnummer: 13945095085
- E-mail: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, China, 161005
- Nog niet aan het werven
- Qiqihar First Hospital
-
Contact:
- Xiyuan Sun, Doctor
- Telefoonnummer: 13945258792
- E-mail: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Nog niet aan het werven
- Henan Cancer Hospital
-
Contact:
- Ying Liu, Doctor
- Telefoonnummer: 13783604602
- E-mail: yaya7207@126.com
-
Zhengzhou, Henan, China, 450000
- Nog niet aan het werven
- The Third People's Hospital of Zhengzhou
-
Contact:
- HaiCun Wang, Master
- Telefoonnummer: 13803833783
- E-mail: whc1975@126.com
-
Zhengzhou, Henan, China, 450000
- Nog niet aan het werven
- The first affiliated hospital of Zhengzhou university
-
Contact:
- Yongxu Jia, Doctor
- Telefoonnummer: 15237128281
- E-mail: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, China, 434099
- Nog niet aan het werven
- Jingzhou First People's Hospital
-
Contact:
- Yan Hu, Master
- Telefoonnummer: 18163137369
- E-mail: helensparkle@163.com
-
Wuhan, Hubei, China, 430022
- Nog niet aan het werven
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Hongli Liu, Doctor
- Telefoonnummer: 13995680822
- E-mail: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Werving
- Hunan Cancer Hospital
-
Contact:
- Yi He, Doctor
- Telefoonnummer: 18692237222
- E-mail: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Werving
- Nanjing Drum Tower Hospital
-
Contact:
- Yudong Qiu, Doctor
- Telefoonnummer: 13951806490
- E-mail: yudongqiu510@163.com
-
Nanjing, Jiangsu, China, 210009
- Werving
- Zhongda Hospital Southeast University
-
Contact:
- CaiLian Wang, Doctor
- Telefoonnummer: 13851756378
- E-mail: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, China, 210000
- Nog niet aan het werven
- Jiangsu Provincial Cancer Hospital
-
Contact:
- Yuanhua Liu, Doctor
- Telefoonnummer: 13305180356
- E-mail: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Nog niet aan het werven
- Jiangxi Provincal People's Hospital
-
Contact:
- Weirong Yao, Doctor
- Telefoonnummer: 13907002901
- E-mail: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Nog niet aan het werven
- Jilin Cancer Hospital
-
Contact:
- Hongxia Cui, Master
- Telefoonnummer: 13504436090
- E-mail: 2503074283@qq.com
-
Changchun, Jilin, China, 130021
- Nog niet aan het werven
- The first hospital of Jilin University
-
Contact:
- Tingting Liang, Doctor
- Telefoonnummer: 15804303776
- E-mail: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Werving
- Liaoning Cancer Hospital & Institute
-
Contact:
- Jingdong Zhang, Doctor
- Telefoonnummer: 18040007878
- E-mail: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Nog niet aan het werven
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Contact:
- Aili Suo, Doctor
- Telefoonnummer: 18991232561
- E-mail: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200127
- Werving
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- XiuYing Xiao, Doctor
- Telefoonnummer: 13564579313
- E-mail: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, China, 710000
- Nog niet aan het werven
- The Second Affiliated Hospital of Air Force Medical University
-
Contact:
- Haichuan Su, Doctor
- Telefoonnummer: 18629190366
- E-mail: cntdgcp@163.com
-
Xi’an, Shanxi, China, 710000
- Nog niet aan het werven
- The First Affiliated Hospital of Air Force Medical University
-
Contact:
- Yongzhan Nie, Doctor
- Telefoonnummer: 15091520001
- E-mail: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300202
- Werving
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Zhanyu Pan, Master
- Telefoonnummer: 18622221256
- E-mail: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, China, 300121
- Nog niet aan het werven
- Tianjin Union Medical Center
-
Contact:
- Mingqing Zhang, Doctor
- Telefoonnummer: 15122875158
- E-mail: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830054
- Nog niet aan het werven
- Xinjiang Medical University Affiliated Tumor Hospital
-
Contact:
- YanLi Qu, Master
- Telefoonnummer: 18160627963
- E-mail: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, China, 323000
- Werving
- Lishui Municipal Central Hospital
-
Contact:
- Yanru Xie, Master
- Telefoonnummer: 13567615770
- E-mail: 43437677@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Actieve vergelijker: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recommended Phase 2 Dose
Tijdsspanne: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Tijdsspanne: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Tijdsspanne: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Half-life
Tijdsspanne: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Tijdsspanne: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Tijdsspanne: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Tijdsspanne: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Tijdsspanne: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Tijdsspanne: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Tijdsspanne: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Tijdsspanne: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Tijdsspanne: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Tijdsspanne: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Darmziekten
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Intestinale neoplasmata
- Rectale ziekten
- Colon Ziekten
- Colorectale neoplasmata
- Therapeutica
- Routes voor het toedienen van geneesmiddelen
- Drugstherapie
- Injecties
Andere studie-ID-nummers
Andere studie-ID-nummers
- TQB2930-Ib/II-02
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .